Diagnosis and Treatment of Polycystic Ovary Syndrome

 

Am Fam Physician. 2016 Jul 15;94(2):106-113.

  Patient information: A handout on this topic is available at http://familydoctor.org/familydoctor/en/diseases-conditions/polycystic-ovary-syndrome.html.

Author disclosure: No relevant financial affiliations.

Polycystic ovary syndrome is the most common endocrinopathy among reproductive-aged women in the United States, affecting approximately 7% of female patients. Although the pathophysiology of the syndrome is complex and there is no single defect from which it is known to result, it is hypothesized that insulin resistance is a key factor. Metabolic syndrome is twice as common in patients with polycystic ovary syndrome compared with the general population, and patients with polycystic ovary syndrome are four times more likely than the general population to develop type 2 diabetes mellitus. Patient presentation is variable, ranging from asymptomatic to having multiple gynecologic, dermatologic, or metabolic manifestations. Guidelines from the Endocrine Society recommend using the Rotterdam criteria for diagnosis, which mandate the presence of two of the following three findings—hyperandrogenism, ovulatory dysfunction, and polycystic ovaries—plus the exclusion of other diagnoses that could result in hyperandrogenism or ovulatory dysfunction. It is reasonable to delay evaluation for polycystic ovary syndrome in adolescent patients until two years after menarche. For this age group, it is also recommended that all three Rotterdam criteria be met before the diagnosis is made. Patients who have marked virilization or rapid onset of symptoms require immediate evaluation for a potential androgen-secreting tumor. Treatment of polycystic ovary syndrome is individualized based on the patient's presentation and desire for pregnancy. For patients who are overweight, weight loss is recommended. Clomiphene and letrozole are first-line medications for infertility. Metformin is the first-line medication for metabolic manifestations, such as hyperglycemia. Hormonal contraceptives are first-line therapy for irregular menses and dermatologic manifestations.

Polycystic ovary syndrome (PCOS) is a complex condition that is most often diagnosed by the presence of two of the three following criteria: hyperandrogenism, ovulatory dysfunction, and polycystic ovaries. Because these findings may have multiple causes other than PCOS, a careful, targeted history and physical examination are required to ensure appropriate diagnosis and treatment. This article provides an algorithmic approach to the care of patients with suspected or known PCOS.

WHAT IS NEW ON THIS TOPIC: POLYCYSTIC OVARY SYNDROME

Recent studies suggest that letrozole (Femara) is associated with higher live-birth and ovulation rates compared with clomiphene in patients with polycystic ovary syndrome.

A 2012 Cochrane review concluded that metformin does not improve fertility in patients with polycystic ovary syndrome.

 Enlarge     Print

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendationEvidence ratingReferences

All women diagnosed with PCOS should be screened for metabolic abnormalities (e.g., type 2 diabetes mellitus, dyslipidemia, hypertension), regardless of body mass index.

C

1921

All women with suspected PCOS should be screened for thyroid disease, hyperprolactinemia, and nonclassical congenital adrenal hyperplasia.

C

19

A calorie-restricted diet is recommended for all patients with PCOS who are overweight. Weight loss has been shown to have a positive effect on fertility and metabolic profile.

A

19, 37

Hormonal contraception (e.g., oral contraceptives) should be used as the initial treatment for menstrual cycle irregularity, hirsutism, and acne in patients with PCOS who are not actively trying to get pregnant.

A

19, 30


PCOS = polycystic ovary syndrome.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendationEvidence ratingReferences

All women diagnosed with PCOS should be screened for metabolic abnormalities (e.g., type 2 diabetes mellitus, dyslipidemia, hypertension), regardless of body mass index.

C

1921

All women with suspected PCOS should be screened for thyroid disease, hyperprolactinemia, and nonclassical congenital adrenal hyperplasia.

C

19

A calorie-restricted diet is recommended for all patients with PCOS who are overweight. Weight loss has been shown to have a positive effect on fertility and metabolic profile.

A

19, 37

Hormonal contraception (e.g., oral contraceptives) should be used as the initial treatment for menstrual cycle irregularity, hirsutism, and acne in patients with PCOS who are not actively trying to get pregnant.

A

19, 30


PCOS = polycystic ovary syndrome.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.

Epidemiology and Pathophysiology

PCOS is the most common endocrinopathy among reproductive-aged women in the United States, affecting approximately 7% of female patients.1 Although its exact etiology is unclear, PCOS is currently thought to emerge from a complex interaction of genetic and environmental traits. Evidence from one twin-family study indicates that there is a strong correlation between familial factors and the presence of PCOS.2

The pathogenesis of PCOS has been linked to altered luteinizing hormone (LH) action, insulin resistance, and a possible predisposition to hyperandrogenism.37 One theory maintains that underlying insulin resistance exacerbates hyperandrogenism by suppressing synthesis of sex hormone–binding globulin and increasing adrenal and ovarian synthesis of androgens, thereby increasing androgen levels. These androgens then lead to irregular menses and physical manifestations of hyperandrogenism.8

Common Comorbidities

PCOS is associated with multiple metabolic defects, including metabolic syndrome. Twice as many women with PCOS have metabolic syndrome as in the general population, and about one-half of women with PCOS are obese.1,9 The presence of PCOS is also associated with a fourfold increase in the risk of type 2 diabetes mellitus.10 There is an increased prevalence of nonalcoholic fatty liver disease,11,12 sleep apnea,13 and dyslipidemia14 in patients with PCOS, even when controlled for body mass index. Rates of cardiovascular disease are higher in patients with PCOS, but increased cardiovascular mortality has not been consistently demonstrated.15,16 Finally, there is evidence to suggest an increased risk of mood disorders among patients with PCOS.17,18

Given the conditions associated with PCOS, the Endocrine Society, the Androgen Excess and PCOS Society, and the American College of Obstetricians and Gynecologists recommend that clinicians evaluate patients' blood pressure at every visit and lipid levels at the time of diagnosis, and screen for type 2 diabetes with a two-hour oral glucose tolerance test regardless of a patient's body mass index. Patients should have repeat diabetes screening every three to five years, or more often if other indications for screening are present.1921 The Endocrine Society further recommends depression screening, as well as screening for symptoms of obstructive sleep apnea in overweight and obese patients with PCOS.19 However, routine screening for nonalcoholic fatty liver disease or endometrial cancer (using ultrasonography) is not recommended.19

Clinical Presentation

The clinical presentation of PCOS is variable. Patients may be asymptomatic or they may have multiple gynecologic, dermatologic, or metabolic manifestations. Patients with PCOS most commonly present with signs of hyperandrogenism and a constellation of oligomenorrhea, amenorrhea, or infertility.19,22 Workup for PCOS is sometimes prompted by an incidental finding of multiple ovarian cysts after ultrasonography.

Diagnostic Workup

The diagnostic workup should begin with a thorough history and physical examination. Clinicians should focus on the patient's menstrual history, any fluctuations in the patient's weight and their impact on PCOS symptoms, and cutaneous findings (e.g., terminal hair, acne, alopecia, acanthosis nigricans, skin tags).19 Patients should also be asked about factors related to common comorbidities of PCOS.

The Endocrine Society advises clinicians to diagnose PCOS using the 2003 Rotterdam criteria (Table 119), although recommendations differ across guidelines.23 According to the Rotterdam criteria, diagnosis requires the presence of at least two of the following three findings: hyperandrogenism, ovulatory dysfunction, and polycystic ovaries.

 Enlarge     Print

Table 1.

Criteria for Diagnosis of PCOS

Clinical findingNational Institutes of Health criteria, 1990 (must have both of the findings marked below)Rotterdam criteria, 2003 (must have any two of the findings marked below)Androgen Excess and PCOS Society, 2009 (must have A plus either B or C)

Hyperandrogenism*

X

X

A

Oligomenorrhea

X

X

B

Polycystic ovaries

X

C


PCOS = polycystic ovary syndrome.

*—Clinical or biochemical evidence of excess androgen.

Information from reference 19.

Table 1.

Criteria for Diagnosis of PCOS

Clinical findingNational Institutes of Health criteria, 1990 (must have both of the findings marked below)Rotterdam criteria, 2003 (must have any two of the findings marked below)Androgen Excess and PCOS Society, 2009 (must have A plus either B or C)

Hyperandrogenism*

X

X

A

Oligomenorrhea

X

X

B

Polycystic ovaries

X

C


PCOS = polycystic ovary syndrome.

*—Clinical or biochemical evidence of excess androgen.

Information from reference 19.

Diagnosis can generally be accomplished with a careful history, physical examination, and basic laboratory testing, without the need for ultrasonography or other imaging. Hyperandrogenism can be diagnosed clinically by the presence of excessive acne, androgenic alopecia, or hirsutism (terminal hair in a male-pattern distribution); or chemically, by elevated serum levels of total, bioavailable, or free testosterone or dehydroepiandrosterone sulfate.23 Measurement of androgen levels is helpful in the rare occasion that an androgen-secreting tumor is suspected (e.g., when a patient has marked virilization or rapid onset of symptoms associated with PCOS).

Ovulatory dysfunction refers to oligomenorrhea (cycles more than 35 days apart but less than six months apart) or amenorrhea (absence of menstruation for six to 12 months after a cyclic pattern has been established).24

A polycystic ovary is defined as an ovary containing 12 or more follicles (or 25 or more follicles using new ultrasound technology) measuring 2 to 9 mm in diameter or an ovary that has a volume of greater than 10 mL on ultrasonography. A single ovary meeting either or both of these definitions is sufficient for diagnosis of polycystic ovaries.23,25 However, ultrasonography of the ovaries is unnecessary unless imaging is needed to rule out a tumor or the patient has met only one of the other Rotterdam criteria for PCOS.19,26 Polycystic ovaries meeting the above parameters can be found in as many as 62% of patients with normal ovulation, with prevalence declining as patients increase in age.27

The goal of further evaluation of suspected PCOS is twofold: to exclude other treatable conditions that can mimic PCOS and to detect and treat long-term metabolic complications. Anovulation is common after menarche, so it is reasonable to delay workup for PCOS in adolescents until they have been oligomenorrheic for at least two years.28 If an adolescent is evaluated for PCOS, it has been suggested that she meet all three of the Rotterdam criteria before being diagnosed with the condition28  (Table 119).

The differential diagnosis of PCOS is broad and includes both endocrinologic and malignant etiologies. Figure 119 provides an algorithm for the workup of select presentations. For any woman with suspected PCOS, the Endocrine Society recommends excluding pregnancy, thyroid dysfunction, hyperprolactinemia, and nonclassical congenital adrenal hyperplasia.19 Depending on presentation, conditions such as hypothalamic amenorrhea and primary ovarian insufficiency should also be excluded. In women with rapid symptom onset or significant virilization, such as deepening voice or clitoromegaly, an androgen-secreting tumor should be ruled out. Finally, Cushing syndrome or acromegaly should be excluded in patients with physical findings that suggest either condition.19 There is no need to order laboratory testing for these conditions if the patient does not have suggestive physical findings.

 Enlarge     Print

Diagnosis of Polycystic Ovary Syndrome

Figure 1.

Diagnosis of polycystic ovary syndrome. (CT = computed tomography; DHEA-S = dehydroepiandrosterone sulfate; FSH = follicle-stimulating hormone; LH = luteinizing hormone; MRI = magnetic resonance imaging; OGTT = oral glucose tolerance test; PCOS = polycystic ovary syndrome; TSH = thyroid-stimulating hormone.)

Information from reference 19.

Diagnosis of Polycystic Ovary Syndrome


Figure 1.

Diagnosis of polycystic ovary syndrome. (CT = computed tomography; DHEA-S = dehydroepiandrosterone sulfate; FSH = follicle-stimulating hormone; LH = luteinizing hormone; MRI = magnetic resonance imaging; OGTT = oral glucose tolerance test; PCOS = polycystic ovary syndrome; TSH = thyroid-stimulating hormone.)

Information from reference 19.

Other tests that may be helpful but are not necessary for diagnosis include measurement of LH and follicle-stimulating hormone (FSH) levels to determine a serum ratio of LH/FSH. A ratio greater than 2 generally indicates PCOS, but there are no exact cutoff values because many different assays are used.26 The FSH level is more helpful in ruling out ovarian failure.26

Treatment

PCOS is a multifaceted syndrome that affects multiple organ systems with significant metabolic and reproductive manifestations. Treatment should be individualized based on the patient's presentation and desire for pregnancy (Figure 219,2935). Devices and medications used to treat manifestations of PCOS, and their associated adverse effects, are described in Table 2.19,2933,36

 Enlarge     Print

Management of Polycystic Ovary Syndrome

Figure 2.

Management of polycystic ovary syndrome. Treatment options vary depending on patient's desire for contraception. Lifestyle modification is a central part of treatment for all manifestations of polycystic ovary syndrome.

Information from references 19, and 29 through 35.

Management of Polycystic Ovary Syndrome


Figure 2.

Management of polycystic ovary syndrome. Treatment options vary depending on patient's desire for contraception. Lifestyle modification is a central part of treatment for all manifestations of polycystic ovary syndrome.

Information from references 19, and 29 through 35.

 Enlarge     Print

Table 2.

Treatments for Polycystic Ovary Syndrome

Medication or deviceDescriptionManifestations treatedFDA pregnancy categoryMain adverse effectsTypical dosageCost*

Clomiphene†

Ovulation induction agent, selective estrogen receptor modulator

Infertility (first-line therapy)19

X

Multiple pregnancy or ovarian hyperstimulation, thromboembolism, visual disturbances

50 to 100 mg daily

$15 for 100 mg daily for 5 days

Eflornithine (Vaniqa)‡§

Inhibits hair growth

Mild hirsutism (second-line therapy)33

C

Mild skin irritation

13.9% cream applied to affected area twice daily

$78 (brand) for 1 30-g tube

Finasteride (Proscar)‡

5-alpha-reductase inhibitor

Hirsutism (weak recommendation because of inconsistent study results)32

X

Hypersensitivity reaction, decreased libido

5 mg daily

$10 (generic) and $273 (brand)

Flutamide‡

Nonsteroidal antiandrogen used mostly for prostate cancer

Hirsutism (safe and effective according to low- to very low-quality evidence) 32

D

Liver toxicity, thrombocytopenia, leukopenia, hot flashes

250 mg once or twice daily32

$32 for 250 mg daily

Hormonal contraceptives (e.g., pill, patch, vaginal ring)‡||

See article for details

Menstrual irregularities, hirsutism, acne (first-line therapy)19,30,32

X

Nausea, headache, spotting, thrombophlebitis, deep venous thrombosis

Varies

Varies

Letrozole (Femara)‡

Nonsteroidal competitive inhibitor of aromatase; inhibits conversion of adrenal androgens

Infertility (first-line therapy)19,29

C

Osteoporosis, thromboembolism, MI, hot flashes, arthralgias

2.5 to 7.5 mg daily for 5 days

$8 (generic) and $128 (brand) for 2.5 mg daily for 5 days

Levonorgestrel-releasing intrauterine system (Mirena)‡

Intrauterine device

Endometrial hyperplasia

X

Amenorrhea, nausea, vomiting; rare complications include the device becoming embedded in the myometrium and uterine perforation

5 years

$815 (not including cost of placement)

Abnormal uterine bleeding (FDA approved)31

Metformin‡

Insulin-sensitizing agent

Insulin resistance (first-line therapy)

B

Gastrointestinal upset, lactic acidosis, increase in homocysteine levels

1,500 to 2,250 mg daily

$4 for 1,000 mg twice daily

Menstrual irregularities (second-line therapy added to hormonal contraceptives)

Hirsutism (third-line therapy added to hormonal contraceptives and spironolactone)19

Spironolactone‡

Antiandrogenic antimineralocorticoid

Hirsutism (second-line therapy added after 6 months of oral contraceptive therapy if not improved)32,33

C

Hyperkalemia, nausea, breast tenderness

50 mg daily to 100 to 200 mg daily

$15 for 100 mg daily

Acne (second-line therapy)


note: Thiazolidinediones have been omitted from the table because the Endocrine Society has determined that their risk-benefit ratio is unfavorable.

FDA = U.S. Food and Drug Administration; MI = myocardial infarction; PCOS = polycystic ovary syndrome.

*—Estimated retail price of one month's treatment (unless otherwise noted) based on information obtained at www.goodrx.com and www.lowestmed.com (accessed May 24, 2015).

†—FDA approved for female infertility caused by PCOS.

‡—Not FDA approved for treatment of manifestations of PCOS.

§—Not studied specifically in women with PCOS; therefore, effectiveness is unknown.

||—Based on mostly anecdotal evidence.

Adapted with permission from Radosh L. Drug treatments for polycystic ovary syndrome. Am Fam Physician. 2009;79(8):672–673, with additional information from references 19, and 29 through 33.

Table 2.

Treatments for Polycystic Ovary Syndrome

Medication or deviceDescriptionManifestations treatedFDA pregnancy categoryMain adverse effectsTypical dosageCost*

Clomiphene†

Ovulation induction agent, selective estrogen receptor modulator

Infertility (first-line therapy)19

X

Multiple pregnancy or ovarian hyperstimulation, thromboembolism, visual disturbances

50 to 100 mg daily

$15 for 100 mg daily for 5 days

Eflornithine (Vaniqa)‡§

Inhibits hair growth

Mild hirsutism (second-line therapy)33

C

Mild skin irritation

13.9% cream applied to affected area twice daily

$78 (brand) for 1 30-g tube

Finasteride (Proscar)‡

5-alpha-reductase inhibitor

Hirsutism (weak recommendation because of inconsistent study results)32

X

Hypersensitivity reaction, decreased libido

5 mg daily

$10 (generic) and $273 (brand)

Flutamide‡

Nonsteroidal antiandrogen used mostly for prostate cancer

Hirsutism (safe and effective according to low- to very low-quality evidence) 32

D

Liver toxicity, thrombocytopenia, leukopenia, hot flashes

250 mg once or twice daily32

$32 for 250 mg daily

Hormonal contraceptives (e.g., pill, patch, vaginal ring)‡||

See article for details

Menstrual irregularities, hirsutism, acne (first-line therapy)19,30,32

X

Nausea, headache, spotting, thrombophlebitis, deep venous thrombosis

Varies

Varies

Letrozole (Femara)‡

Nonsteroidal competitive inhibitor of aromatase; inhibits conversion of adrenal androgens

Infertility (first-line therapy)19,29

C

Osteoporosis, thromboembolism, MI, hot flashes, arthralgias

2.5 to 7.5 mg daily for 5 days

$8 (generic) and $128 (brand) for 2.5 mg daily for 5 days

Levonorgestrel-releasing intrauterine system (Mirena)‡

Intrauterine device

Endometrial hyperplasia

X

Amenorrhea, nausea, vomiting; rare complications include the device becoming embedded in the myometrium and uterine perforation

5 years

$815 (not including cost of placement)

Abnormal uterine bleeding (FDA approved)31

Metformin‡

Insulin-sensitizing agent

Insulin resistance (first-line therapy)

B

Gastrointestinal upset, lactic acidosis, increase in homocysteine levels

1,500 to 2,250 mg daily

$4 for 1,000 mg twice daily

Menstrual irregularities (second-line therapy added to hormonal contraceptives)

Hirsutism (third-line therapy added to hormonal contraceptives and spironolactone)19

Spironolactone‡

Antiandrogenic antimineralocorticoid

Hirsutism (second-line therapy added after 6 months of oral contraceptive therapy if not improved)32,33

C

Hyperkalemia, nausea, breast tenderness

50 mg daily to 100 to 200 mg daily

$15 for 100 mg daily

Acne (second-line therapy)


note: Thiazolidinediones have been omitted from the table because the Endocrine Society has determined that their risk-benefit ratio is unfavorable.

FDA = U.S. Food and Drug Administration; MI = myocardial infarction; PCOS = polycystic ovary syndrome.

*—Estimated retail price of one month's treatment (unless otherwise noted) based on information obtained at www.goodrx.com and www.lowestmed.com (accessed May 24, 2015).

†—FDA approved for female infertility caused by PCOS.

‡—Not FDA approved for treatment of manifestations of PCOS.

§—Not studied specifically in women with PCOS; therefore, effectiveness is unknown.

||—Based on mostly anecdotal evidence.

Adapted with permission from Radosh L. Drug treatments for polycystic ovary syndrome. Am Fam Physician. 2009;79(8):672–673, with additional information from references 19, and 29 through 33.

A team approach involving care by primary care and subspecialist physicians can be helpful to address the multiple manifestations of the syndrome. Goals for treatment (e.g., treating infertility; regulating menses for endometrial protection; controlling hyperandrogenic features, including hirsutism and acne) must account for the patient's preferences because therapy selection may otherwise conflict with outcomes that the patient considers important. Metabolic complications should be addressed in every patient via a blood pressure evaluation, a lipid panel, and a two-hour oral glucose tolerance test. Patients who are overweight should be evaluated for signs and symptoms of obstructive sleep apnea. All patients should be screened for depression (Figure 119).

ANOVULATION AND INFERTILITY

Lifestyle modification and weight reduction reduce insulin resistance and can significantly improve ovulation. Therefore, lifestyle modification is first-line therapy for women who are overweight.37 A calorie-restricted diet is recommended for all patients with PCOS who are overweight. Weight loss has been shown to have a positive effect on fertility and metabolic profile.19,30 The Endocrine Society recommends clomiphene or letrozole (Femara) for ovulation induction. Recent studies suggest that letrozole is associated with higher live-birth rates and ovulation rates compared with clomiphene in patients with PCOS.29 The impact of metformin on fertility is controversial; although it was once believed to improve infertility, a 2012 Cochrane review concluded that it does not.38

MENSTRUAL IRREGULARITY

In a patient not seeking pregnancy, the Endocrine Society recommends hormonal contraception (i.e., oral contraceptive, dermal patch, or vaginal ring) as the initial medication for treatment of irregular menses and hyperandrogenism manifesting as acne or hirsutism.19,30 Small studies have shown that metformin can restore regular menses in up to 50% to 70% of women with PCOS,39,40 but oral contraceptives have been shown to be superior to metformin for regulating menses and lowering androgen levels.30 There are no studies demonstrating superiority of one oral contraceptive over another in treating PCOS. Prevention of endometrial hyperplasia from chronic anovulation may be accomplished either by progesterone derivatives, progestin-containing oral contraceptives, or the levonorgestrel-releasing intrauterine system (Mirena).31,41 Patient comfort and preference should also be taken into account when treating irregular menses.

HIRSUTISM

Hirsutism is a bothersome hyperandrogenic manifestation of PCOS that may require at least six months of treatment before improvement begins. According to a 2015 Cochrane review, the most effective first-line therapy for mild hirsutism is oral contraceptives.32 Spironolactone, 100 mg daily, and flutamide, 250 mg twice daily, are safe for patient use, but the evidence for their effectiveness is minimal.32 Other therapies include eflornithine (Vaniqa), electrolysis, or light-based therapies such as lasers and intense pulsed light. Any of these can be used as monotherapy in mild cases or as adjunctive therapy in more severe cases.33

ACNE

Acne is common in the general population and in patients with PCOS. Hormonal contraceptives are first-line medications for treating acne associated with PCOS and can be used in conjunction with standard topical acne therapy (e.g., retinoids, antibiotics, benzoyl peroxide) or as monotherapy.19,34 Antiandrogens, spironolactone being the most common, can be added as second-line medications.19,34

Areas for Future Research

More research is needed to clarify the complex pathophysiology of PCOS. No single test is currently available for its diagnosis. Additionally, once diagnosis is established, the options for treatment are of limited number and effectiveness because they target only the symptoms of PCOS. Finally, patients with PCOS have higher rates of metabolic complications, such as cardiovascular disease, but their impact on mortality is not clear. Therefore, more prospective epidemiologic studies on the topic are necessary.

Data Sources: PubMed, the Cochrane database, UpToDate, and Dynamed were searched using the key terms polycystic ovarian syndrome, metabolic syndrome, infertility, and diagnosis and treatment. The search included meta-analyses, randomized controlled trials, clinical trials, and reviews. Search dates: April 2015 and March 2016.

This review updates previous articles on this topic by Richardson35; Radosh36; and Hunter and Sterrett.42

The Authors

show all author info

TRACY WILLIAMS, MD, is the associate director of Via Christi Family Medicine Residency, Wichita, Kan., and an assistant professor in the Department of Family and Community Medicine at the University of Kansas School of Medicine–Wichita....

RAMI MORTADA, MD, is an assistant professor in the Department of Internal Medicine, Division of Endocrinology, at the University of Kansas School of Medicine–Wichita.

SAMUEL PORTER, MD, is a resident at Via Christi Family Medicine Residency.

Address correspondence to Tracy Williams, MD, Via Christi Family Medicine Residency, 707 N. Emporia, Wichita, KS 67214 (e-mail: tracy.williams@via-christi.org). Reprints are not available from the authors.

Author disclosure: No relevant financial affiliations.

REFERENCES

show all references

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745–2749....

2. Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab. 2006;91(6):2100–2104.

3. Dafopoulos K, Venetis C, Pournaras S, Kallitsaris A, Messinis IE. Ovarian control of pituitary sensitivity of luteinizing hormone secretion to gonadotropin-releasing hormone in women with the polycystic ovary syndrome. Fertil Steril. 2009;92(4):1378–1380.

4. Jakimiuk AJ, Weitsman SR, Navab A, Magoffin DA. Luteinizing hormone receptor, steroidogenesis acute regulatory protein, and steroidogenic enzyme messenger ribonucleic acids are overexpressed in thecal and granulosa cells from polycystic ovaries. J Clin Endocrinol Metab. 2001;86(3):1318–1323.

5. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774–800.

6. Kumar A, Woods KS, Bartolucci AA, Azziz R. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2005;62(6):644–649.

7. Korhonen S, Hippeläinen M, Niskanen L, Vanhala M, Saarikoski S. Relationship of the metabolic syndrome and obesity to polycystic ovary syndrome: a controlled, population-based study. Am J Obstet Gynecol. 2001;184(3):289–296.

8. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005;83(5):1454–1460.

9. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism. 2003;52(7):908–915.

10. Celik C, Tasdemir N, Abali R, Bastu E, Yilmaz M. Progression to impaired glucose tolerance or type 2 diabetes mellitus in polycystic ovary syndrome: a controlled follow-up study. Fertil Steril. 2014;101(4):1123–1128.e1.

11. Karoli R, Fatima J, Chandra A, Gupta U, Islam FU, Singh G. Prevalence of hepatic steatosis in women with polycystic ovary syndrome. J Hum Reprod Sci. 2013;6(1):9–14.

12. Setji TL, Holland ND, Sanders LL, Pereira KC, Diehl AM, Brown AJ. Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(5):1741–1747.

13. Vgontzas AN, Legro RS, Bixler EO, Grayev A, Kales A, Chrousos GP. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab. 2001;86(2):517–520.

14. Phelan N, O'Connor A, Kyaw-Tun T, et al. Lipoprotein subclass patterns in women with polycystic ovary syndrome (PCOS) compared with equally insulin-resistant women without PCOS. J Clin Endocrinol Metab. 2010;95(8):3933–3939.

15. Wang ET, Cirillo PM, Vittinghoff E, Bibbins-Domingo K, Cohn BA, Cedars MI. Menstrual irregularity and cardiovascular mortality. J Clin Endocrinol Metab. 2011;96(1):E114–E118.

16. Schmidt J, Landin-Wilhelmsen K, Brännström M, Dahlgren E. Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study. J Clin Endocrinol Metab. 2011;96(12):3794–3803.

17. Bhattacharya SM, Jha A. Prevalence and risk of depressive disorders in women with polycystic ovary syndrome (PCOS). Fertil Steril. 2010;94(1):357–359.

18. Veltman-Verhulst SM, Boivin J, Eijkemans MJ, Fauser BJ. Emotional distress is a common risk in women with polycystic ovary syndrome: a systematic review and meta-analysis of 28 studies. Hum Reprod Update. 2012;18(6):638–651.

19. Legro RS, Arslanian SA, Ehrmann DA, et al.; Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565–4592.

20. Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE. Glucose intolerance in polycystic ovary syndrome—a position statement of the Androgen Excess Society. J Clin Endocrinol Metab. 2007;92(12):4546–4556.

21. ACOG Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 108: Polycystic ovary syndrome. Obstet Gynecol. 2009;114(4):936–949.

22. Mani H, Davies MJ, Bodicoat DH, et al. Clinical characteristics of polycystic ovary syndrome: investigating differences in white and South Asian women. Clin Endocrinol (Oxf). 2015;83(4):542–549.

23. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25.

24. Woolcock JG, Critchley HO, Munro MG, Broder MS, Fraser IS. Review of the confusion in current and historical terminology and definitions for disturbances of menstrual bleeding. Fertil Steril. 2008;90(6):2269–2280.

25. Dewailly D, Lujan ME, Carmina E, et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2014;20(3):334–352.

26. Azziz R, Carmina E, Dewailly D, et al.; Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456–488.

27. Johnstone EB, Rosen MP, Neril R, et al. The polycystic ovary post-Rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance. J Clin Endocrinol Metab. 2010;95(11):4965–4972.

28. Carmina E, Oberfield SE, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol. 2010;203(3):201.e1–201.e5.

29. Legro RS, Brzyski RG, Diamond MP, et al.; NICHD Reproductive Medicine Network. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome [published correction appears in N Engl J Med. 2014; 317(15):1465]. N Engl J Med. 2014;371(2):119–129.

30. Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev. 2007;(1):CD005552.

31. Bayer LL, Hillard PJ. Use of levonorgestrel intrauterine system for medical indications in adolescents. J Adolesc Health. 2013;52(4 suppl):S54–S58.

32. van Zuuren EJ, Fedorowicz Z, Carter B, Pandis N. Interventions for hirsutism (excluding laser and photoepilation therapy alone). Cochrane Database Syst Rev. 2015;(4):CD010334.

33. Somani N, Turvy D. Hirsutism: an evidence-based treatment update. Am J Clin Dermatol. 2014;15(3):247–266.

34. Buzney E, Sheu J, Buzney C, Reynolds RV. Polycystic ovary syndrome: a review for dermatologists: Part II. Treatment. J Am Acad Dermatol. 2014;71(5):859.e1–859.e15.

35. Richardson MR. Current perspectives in polycystic ovary syndrome. Am Fam Physician. 2003;68(4):697–704.

36. Radosh L. Drug treatments for polycystic ovary syndrome. Am Fam Physician. 2009;79(8):671–676.

37. Harrison CL, Lombard CB, Moran LJ, Teede HJ. Exercise therapy in polycystic ovary syndrome: a systematic review. Hum Reprod Update. 2011;17(2):171–183.

38. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and sub-fertility. Cochrane Database Syst Rev. 2012;(5):CD003053.

39. Romualdi D, De Cicco S, Tagliaferri V, Proto C, Lanzone A, Guido M. The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2011;96(5):E821–E824.

40. Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab. 2000;85(1):139–146.

41. Dumesic DA, Lobo RA. Cancer risk and PCOS. Steroids. 2013;78(8):782–785.

42. Hunter MH, Sterrett JJ. Polycystic ovary syndrome: it's not just infertility. Am Fam Physician. 2000;62(5):1079–1088.

 

 

Copyright © 2016 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


More in AFP


Editor's Collections


Related Content


More in Pubmed

MOST RECENT ISSUE


Aug 15, 2017

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article